TMCnet News

Detailed Overview of the Secondary Progressive Multiple Sclerosis (SPMS) Market 2017 - Forecasts to 2030 - Research and Markets

[December 05, 2017]

Detailed Overview of the Secondary Progressive Multiple Sclerosis (SPMS) Market 2017 - Forecasts to 2030 - Research and Markets

The "Secondary Progressive Multiple Sclerosis (SPMS) - A Detailed Overview" report has been added to Research and Markets' offering.

This report provides an overview of secondary progressive multiple sclerosis (SPMS) disease indication in detail, highlights SPMS epidemiology in key geographies, elaborates on the drugs prescribed and expected to be prescribed in SPMS and covers the market in detail in terms of drugs and countries by sales value and patient numbers, in addition to forecasts. The report elaborates on the Secondary Progressive Multiple Sclerosis disease indication detailing the definition, causes, profile of SPMS patients, symptoms of SPMS patients, and the disease progression in SPMS patients.

The report further highlights the multiple methods through which the patient can be diagnosed for SPMS. The next part of the report consists of SPMS epidemiology and prevalence in key geographies across the globe such as the US, the UK, Germany, Italy, France, Spain and Japan. The epidemiology for SPMS indication across key geographies has bee forecasted to 2024. The next part of the report highlights the importance of factors influencing the physician prescription decisions in SPMS like efficacy factors, tolerability factors, monitoring requirements and pricing factors.

The report further details the drugs prescribed or expected to be prescribed in SPMS by the physicians in terms of details about the formulation, molecule, mode of administration and MoA of the drugs, their patent and trial details and the expected impact of the drug in the SPMS market. The report further details the drug attribute analysis on each parameter considered important in the prescription of SPMS drugs.

The report also covers other products which are currently in the pipeline for SPMS and other progressive forms of MS. The final part of the report provides a detailed overview of the SPMS market sizing drug wise and geography wise both in terms of sales value and patient numbers. The drugs have been forecasted to 2030 both for sales value and patient numbers geography wise.

Key Topics Covered:

1. Multiple Sclerosis Definition

2. Types of Multiple Sclerosis

3. Secondary Progressive Relapsing MS Defined

4. Causes of SPMS

5. Profile of SPMS Patient

6. Symptoms of SPMS

7. Disease progression and impact on QoL

8. Disease Diagnosis

9. Disease Epidemiology

10. Factors impacting a physician's prescription decision

11. Disease Modifying Therapies for SPMS